Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Dr, Mark Williams ??

<< Previous

Bullboard Posts

Next >>

Comment by talisman47on Dec 17, 2020 6:37pm

201 Views

Post# 32136664

RE:RE:RE:RE:Dr, Mark Williams ??

I don't know what the truth might be. I sent an email to Algernon this afternoon with the Marvel link attached and asked them to clarify . Is Mark Williams working for both companies, will he be leaving Algernon ??? .....I asked them to clarify.

Let's see if I get a respones from them. Will post it if I get one.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features